UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) Merus N.V. (Nasdaq: MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative
F-star Granted Composition of Matter Patent for FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1
Patent protects Company’s lead clinical asset FS118 throughout Europe
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announces the European Patent Office (EPO) has granted a patent with claims protecting the composition of matter of F-star’s FS118 molecule throughout Europe. The expiry date of the patent, not including any potential extensions to the standard 20-year term of protection, is expected to be June 2037.